Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease
Hepmarc:一项为期 96 周的随机对照可行性试验,研究在 HIV 合并非酒精性脂肪肝患者中添加马拉维罗克的疗效。
期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0288598
Bradshaw, Daniel; Abramowicz, Iga; Bremner, Stephen; Verma, Sumita; Gilleece, Yvonne; Kirk, Sarah; Nelson, Mark; Housman, Rosalie; Miras, Helena; Orkin, Chloe; Fox, Ashini; Curnock, Michael; Jennings, Louise; Gompels, Mark; Clarke, Emily; Robinson, Rachel; Lambert, Pauline; Chadwick, David; Perry, Nicky